Human Milk Oligosaccharides (HMOs) Market (2025-2032)
The Human Milk Oligosaccharides (HMOs) market was valued at $0.35 billion in 2024. This market is expected to reach $1.71 billion by 2032 from an estimated $0.45 billion in 2025, at a CAGR of 21.2% during the forecast period from 2025 to 2032. Human Milk Oligosaccharides (HMOs) Market Size & Forecast The
- Published
- Oct 2024
- Pages
- 220
- Format
- PDF + Excel
- Report ID
- MRFB - 1041382
- Base year
- 2025
- 2024 · HISTORICAL
- $350.0M
- 2032
- $1.71B
- CAGR 2025–2032
- 21.2%
2024 baseline · 2025–2032 forecast at 21.2% CAGR · hover a bar for the value
Key highlights
By Type: In 2025, the 2’FL Segment to Dominate the Human Milk Oligosaccharides (HMOs) Market
By Concentration: In 2025, the Neutral Segment is Expected to Dominate the Human Milk Oligosaccharides (HMOs) Market
By Application: In 2025, the Infant Formula Segment is Expected to Dominate the Human Milk Oligosaccharides (HMOs) Market
By Geography: North America to Dominate the Human Milk Oligosaccharides (HMOs) Market in 2025
Report summary
| Particulars | Details |
|---|---|
| Number of Pages | 220 |
| Format | |
| Forecast Period | 2025–2032 |
| Base Year | 2025 |
| CAGR | 21.2% |
| Market Size | USD 1.71 Billion by 2032 |
| Segments Covered | By Type · 2’FL · 3’FL · 3’SL · 6’SL · LNT · LNnT · DFL · By Concentration · Neutral · Acidic · By Application · Infant Formula · Dietary Supplements · Food & Beverages · Other Applications |
| Countries Covered | North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, Netherlands, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Malaysia, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentina, and Rest of Latin America), and the Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa) |
| Key Companies | Chr. Hansen A/S (A part of Novonesis) (Denmark), DSM-Firmenich AG (Switzerland), Kyowa Hakko Europe GmbH (Germany), Royal FrieslandCampina N.V. (Netherlands), ZuChem Inc. (U.S.), ELICITYL S.A. (France), Dextra Laboratories Limited (U.K.), Glycosyn LLC (U.S.), Nestle Health Science (U.S.), Biosynth Ltd (U.K.), Inbiose NV (Belgium), BASF SE (Germany), and Abbott Laboratories (U.S.) |
Report overview
Segments covered: type, concentration. Regions: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.
The growth of this market is driven by the rising demand for infant nutrition and dietary supplements, increasing awareness regarding the benefits of HMOs, and increased product innovation by various human milk oligosaccharides (HMOs) manufacturers. Moreover, increasing technological advancements and government approvals for the use of HMOs for human consumption are expected to generate growth opportunities.
Report infographic
-Market.webp)
Market dynamics
3 factors across 2 forcesRising Demand for Infant Nutrition
The demand for infant nutrition is increasing, driven by its associated benefits and the growing availability of diverse products in the market. With the global population projected to rise by nearly 2 billion, from 8 billion in 2022 to 9.7 billion by 2050, the expanding infant population is expected to further boost the demand for infant nutrition.
However, the increase in dual-income households, coupled with a growing population of working mothers, has heightened the reliance on convenient, ready-to-use infant nutrition products. Additionally, there is a rising awareness among parents regarding their children’s nutritional needs for cognitive and physical development. As a result, many parents are choosing products that meet these nutritional requirements, often opting for organic and allergen-free options. These trends are significantly driving the growth of the HMO market.
Increasing Awareness Regarding the Benefits of HMO
In recent years, the demand for infant nutrition has surged significantly, with HMOs gaining traction due to their various health benefits for infants. Parents are increasingly aware of the importance of incorporating HMOs into their baby's daily nutrition. Furthermore, due to their substantial health advantages, many consumers are opting for dietary supplements that contain HMOs.
HMOs play a crucial role in infants' health by enhancing immune function through the promotion of beneficial gut bacteria and acting as decoys for pathogens, thereby lowering the risk of infections. Additionally, HMOs contribute to cognitive development by supporting brain growth during early life stages. They also improve gastrointestinal health by fostering beneficial bacteria in the gut microbiome, which is essential for overall health and well-being. These factors have led to increased utilization of HMOs in various supplements, and the growing awareness of their benefits is further supporting market growth.
Table of contents
11 chapters · 113 sections · 220 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Type | 2’FL | — |
By Type
- The 2’FL segment is expected to account for the largest share of the human milk oligosaccharides (HMOs) market.
- The substantial market share of this segment is primarily driven by its high product availability since its approval in 2016, a growing preference for HMOs due to their numerous health benefits and diverse applications, an increasing demand for infant formulas containing HMOs, and the rising incorporation of 2'FL into these infant formula products.
Geographic analysis
North America
Largest shareIn 2025, North America is estimated to account for the largest share of the global Human Milk Oligosaccharides (HMOs) market. North America’s significant share of the human milk oligosaccharides (HMOs) market can be primarily attributed to heightened awareness of the health benefits of HMOs, increasing consumer preference for HMO-based products, a growing trend toward personalized nutrition with a focus on gut health, technological advancements in the region, and strong government support for regulatory frameworks and policies. North America Dominates the Human Milk Oligosaccharides (HMOs) Market in 2025
Asia-Pacific
Fastest growthHowever, the Asia-Pacific region is slated to register the highest CAGR during the forecast period. This growth is driven by increasing preferences for infant nutrition, a rising infant population in the region, higher spending on health-related products, and expanding product offerings from key market players.
Competitive landscape
- January 2025
Royal FrieslandCampina N.V. (Netherlands) got approval for its 2’-Fucosyllactose (2’-FL) ingredient, Aequival, in Thailand to use in infant formula.
- January 2025
DSM-Firmenich AG (Switzerland) received approval for four more human milk oligosaccharide (HMO) ingredients by Food Standards Australia New Zealand (FSANZ) to use in infant formula.
- January 2025
Kyowa Hakko Bio Co., Ltd. (Japan) partnered with the Agency for Science, Technology, and Research (A*STAR) to advance research on Human Milk Oligosaccharides (HMOs).
- November 2024
Nestle Health Science (U.S.) launched a milk solution containing HMOs (Human Milk Oligosaccharides) for early-life nutrition in mainland China under the Wyeth Illume brand.
- July 2024
DSM-Firmenich AG (Switzerland) expanded its presence in the human milk oligosaccharide (HMO) portfolio in China by submitting two new ingredients to the China National Center for Food Safety Risk Assessment (CFSA) and National Health Committee (NHC).
- February 2024
DSM-Firmenich AG (Switzerland) received approval for its HMO ingredient – GlyCare 3FL, for applications in food and dietary supplements in the US and Australia.
- Chr. Hansen A/S (A part of Novonesis) · Denmark
- DSM-Firmenich AG · Switzerland
- Kyowa Hakko Europe GmbH · Germany
- Royal FrieslandCampina N.V. · Netherlands
- ZuChem Inc. (U.S.)
- ELICITYL S.A. · France
- Dextra Laboratories Limited (U.K.)
- Glycosyn LLC (U.S.)
- Nestle Health Science (U.S.)
- Biosynth Ltd (U.K.)
- Inbiose NV · Belgium
- BASF SE · Germany
- Abbott Laboratories (U.S.)
Frequently asked questions
The global human milk oligosaccharides (HMOs) market size was valued at $0.35 billion in 2024.
Cite this report
Meticulous Research. (2024). Human Milk Oligosaccharides (HMOs) Market - Global Opportunity Analysis and Industry Forecasts (2025-2032) (Report No. MRFB - 1041382). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/human-milk-oligosaccharides-(hmos)-market-6065